Year-to-Date Gains: 100%
I don’t usually recommend companies that are losing money, but Mazor Robotics (MZOR) is an exception and I believe it is at the beginning of a very long run. Mazor is based in Israel and its Renaissance guidance system is transforming spinal surgery.
The potential market for Mazor is estimated by some to be as much as $14 billion. While such numbers are always wildly inflated and should be taken with a grain of salt, the estimate still gives you an idea of just how big the opportunity is — especially considering Mazor’s revenue in the first six months of the year was just $11.8 million.
No wonder Mazor Robotics stock has been sizzling. MZOR began trading as an ADR in late May and, in less than five months, has doubled in price to over $20.
Smart money believes in the stock too. Larry Feinberg runs a healthcare hedge fund and his firm invested $7.5 million in Mazor back in August 2012, and another $7.5 million over the summer. It’s not his biggest investment by a long shot — but it just might turn out to be one of his best.
As of this writing, Will Ashworth did not hold a position in any of the aforementioned securities.